Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21790282 | 0.86 | ALDH1A1 (0.32) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL25364272 | 0.86 | ALDH1A1 (0.32) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL29523419 | 0.82 | ALDH1A1 (0.33) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL31346242 | 0.80 | CHRM2 (0.33) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL29523467 | 0.79 | TSHR (0.32) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL1861180 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL393307 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL1861179 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL30693992 | 0.78 | ALDH1A1 (0.34) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL30693996 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 2338/4885TSHR 1662/4885MEN1 1035/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ALDH1A1 2338/4885TSHR 1662/4885MEN1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.